CytomX Therapeutics, Inc. (CTMX)

NMS – Цена в реальном времени. Валюта: USD

3.48

+0.03 (0.87%)

Рынок открыт: Aug 12, 2026, 12:26 PM EDT

3.50

+0.05 (1.45%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

07.08.2026

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

07.08.2026

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers.

07.08.2026

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to break-even earnings per share a year ago.

06.08.2026

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing.

03.08.2026

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Alejandra Carvajal as Chief Legal Officer.

CytomX Therapeutics, Inc. (CTMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

Видео

No Data

Пресс-релизы

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

Search stocks

CytomX Therapeutics, Inc. (CTMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

Видео

No Data

Пресс-релизы

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer